The Tuberculosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Tuberculosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tuberculosis Market.

Some of the key takeaways from the Tuberculosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Tuberculosis treatment therapies with a considerable amount of success over the years. 
• Tuberculosis companies working in the treatment market are GlobeImmune, PDS Biotechnology, BioNTech, GlaxoSmithKline, Archivel Farma, GC Biopharma, Biofabri, Serum Institute of India Pvt. Ltd., Biofabri, S.L, Qurient Co., Shanghai Jiatan Pharmatech, Global Alliance for TB Drug Development, PDS Biotechnology, Theravectys, and others, are developing therapies for the Tuberculosis treatment 

• Emerging Tuberculosis therapies in the different phases of clinical trials are-  GI-18000, PDS0201, BNT164, GSK2556286, GSK3036656, GC3107A, MTBVAC, VPM1002, MTBVAC, RUTI, Telacebec, WX-081, TBAJ-876, PDS 0201, Tuberculosis disease program, and others are expected to have a significant impact on the Tuberculosis market in the coming years.   
• In January 2022, The Phase Transition Success Rate (PTSR) for GlaxoSmithKline’s GSK-3036656 increased by seven points to 55% after the completion of its Phase II pulmonary tuberculosis trial
• In March 2022, The Spanish biopharmaceutical company Biofabri and Bharat Biotech partnered to create, produce, and sell MTBVAC, a novel tuberculosis vaccine. More than 70 nations, primarily in Southeast Asia and sub-Saharan Africa, will have access to TB vaccines thanks to the agreement
• In April 2022, A new partnership between Moderna and the nonprofit scientific research group IAVI has been formed to use mRNA technology to combat a number of global health challenges, such as HIV/AIDS, tuberculosis (TB), antibiotic-resistant enteric infections, and COVID-19
• In March 2022, A cooperation between Bharat Biotech and Biofabri was formed to develop, produce, and sell a novel tuberculosis vaccine. Due to its advanced state of clinical development and the encouraging outcomes of its Phase-I and Phase-II clinical studies, Bharat Biotech chose this vaccine candidate
• In September 2022, In areas of Sub-Saharan Africa where tuberculosis is endemic, Biofabri started a Phase III randomised, double-blind, controlled trial to assess the efficacy, safety, and immunogenicity of MTBVAC in healthy HIV unexposed and HIVexposed uninfected infants
• In July 2021, In order to collaborate on effectiveness studies of the tuberculosis (TB) vaccine candidate MTBVAC, Biofabri and IAVI declared their intention to do so. In collaboration with the University of Zaragoza, IAVI, and the European-based Tuberculosis Vaccine Initiative (TBVI), Biofabri, a subsidiary of the Zendal Group, was granted an in-license to produce and develop the candidate, which was created by the Spanish researcher Dr. Carlos Martin from the University of Zaragoza

Tuberculosis Overview

Mycobacterium tuberculosis, an ancient cause of tuberculosis in humans, mostly affects the lungs, making pulmonary illness the most typical presentation. The respiratory system, gastrointestinal (GI) system, lymphoreticular system, skin, central nervous system, musculoskeletal system, reproductive system, and liver are the organ systems most frequently impacted.

Get a Free Sample PDF Report to know more about Tuberculosis Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/tuberculosis-pipeline-insight

Emerging Tuberculosis Drugs Under Different Phases of Clinical Development Include:

• GI-18000: GlobeImmune
• PDS0201: PDS Biotechnology
• BNT164: BioNTech
• Telacebec (Q203): Qurient Co
• VPM1002: Serum Institute of India
• GSK2556286: GlaxoSmithKline
• GSK3036656: GlaxoSmithKline
• RUTI: Archivel Farma
• GC3107A: GC Biopharma
• MTBVAC: Biofabri

Route of Administration

Tuberculosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Tuberculosis Pipeline Therapeutics Assessment

• Tuberculosis Assessment by Product Type
• Tuberculosis By Stage and Product Type
• Tuberculosis Assessment by Route of Administration
• Tuberculosis By Stage and Route of Administration
• Tuberculosis Assessment by Molecule Type
• Tuberculosis by Stage and Molecule Type

DelveInsight’s Tuberculosis Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Tuberculosis product details are provided in the report. Download the Tuberculosis pipeline report to learn more about the emerging Tuberculosis therapies

Some of the key companies in the Tuberculosis Therapeutics Market include:

Key companies developing therapies for Tuberculosis are – Serum Institute of India Pvt. Ltd., AnHui Longcom Biologic Pharmacy, Biofabri, S.L, Immunitor LLC, Shanghai Jiatan Pharmatech, GlaxoSmithKline, Archivel Farma S.L., LegoChem Biosciences, Quratis Inc, Qurient Co., Sequella, Inc., Vaxil Biotherapeutics, Tianjin CanSino Biotechnology, Global Alliance for TB Drug Development, BioNtech, TaBriX, Moderna, GC Biopharma, AJ Vaccines, Vaxxit Srl, Vaxil Bio Therapeutics, Vaxine Pty Ltd,  TVAX Biomedical, Theravectys SA, Tydockpharma, PDS Biotechnology, PAI lifesciences, EpiVax, Inc., GlobeImmune Inc., Zymergen, Jiangsu Recbio Technology, and others.

Tuberculosis Pipeline Analysis:

The Tuberculosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Tuberculosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Tuberculosis Treatment.
• Tuberculosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Tuberculosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Tuberculosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Tuberculosis drugs and therapies

Tuberculosis Pipeline Market Drivers

• Increasing R&D Investments and new drug developments, rising incidence of Tuberculosis are some of the important factors that are fueling the Tuberculosis Market.

Tuberculosis Pipeline Market Barriers

• However, high pricing of drugs specially second line treatment, lack of TB diagnostics and other factors are creating obstacles in the Tuberculosis Market growth.

Scope of Tuberculosis Pipeline Drug Insight    

• Coverage: Global
• Key Tuberculosis Companies: GlobeImmune, PDS Biotechnology, BioNTech, GlaxoSmithKline, GlaxoSmithKline, Archivel Farma, GC Biopharma, Biofabri, Serum Institute of India Pvt. Ltd., Biofabri, S.L, Qurient Co., Shanghai Jiatan Pharmatech, Global Alliance for TB Drug Development, PDS Biotechnology, Theravectys, and others
• Key Tuberculosis Therapies: GI-18000, PDS0201, BNT164, GSK2556286, GSK3036656, GC3107A, MTBVAC, VPM1002, MTBVAC, RUTI, Telacebec, WX-081, TBAJ-876, PDS 0201, Tuberculosis disease program, and others
• Tuberculosis Therapeutic Assessment: Tuberculosis current marketed and Tuberculosis emerging therapies
• Tuberculosis Market Dynamics: Tuberculosis market drivers and Tuberculosis market barriers 

Request for Sample PDF Report for Tuberculosis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/